Use of tumor necrosis factor‐alpha inhibitors during pregnancy among women who delivered live born infants

To describe the use of tumor necrosis factor‐alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC).

[1]  T. Kvien,et al.  Epidemiological Aspects of Rheumatoid Arthritis , 2006, Annals of the New York Academy of Sciences.

[2]  Barbara Evans,et al.  A policy framework for public health uses of electronic health data , 2012, Pharmacoepidemiology and drug safety.

[3]  Karin E. Johnson,et al.  Validation of an algorithm to estimate gestational age in electronic health plan databases , 2013, Pharmacoepidemiology and drug safety.

[4]  B. Nørgård,et al.  The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease , 2017, Inflammatory bowel diseases.

[5]  Sengwee Toh,et al.  Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program , 2016, Maternal and Child Health Journal.

[6]  Richard Platt,et al.  The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction , 2012, Pharmacoepidemiology and drug safety.

[7]  Marsha A Raebel,et al.  Design considerations, architecture, and use of the Mini‐Sentinel distributed data system , 2012, Pharmacoepidemiology and drug safety.

[8]  M. Dubinsky,et al.  Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  H. Saito,et al.  Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum , 2009, Annals of the rheumatic diseases.

[10]  E. Loftus.  Update on the Incidence and Prevalence of Inflammatory Bowel Disease in the United States. , 2016, Gastroenterology & hepatology.

[11]  C. Chambers,et al.  Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. , 2012, Birth defects research. Part A, Clinical and molecular teratology.

[12]  Rosa Parisi,et al.  Global epidemiology of psoriasis: a systematic review of incidence and prevalence. , 2013, The Journal of investigative dermatology.

[13]  X. Mariette,et al.  OP0017 Lack of placental transfer of certolizumab pegol during pregnancy: results from crib, a prospective, postmarketing, multicenter, pharmacokinetic study , 2017, European Journal of Obstetrics, Gynecology, and Reproductive Biology.

[14]  M. Ostensen,et al.  The Effect of Pregnancy on Ankylosing Spondylitis, Psoriatic Arthritis, and Juvenile Rheumatoid Arthritis , 1992, American journal of reproductive immunology.

[15]  L. Espinoza,et al.  Epidemiology of Psoriasis and Psoriatic Arthritis , 2016 .

[16]  P. Villiger,et al.  A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments , 2004, Annals of the rheumatic diseases.

[17]  Y. Falck‐Ytter,et al.  AGA American Gastroenterological Association Institute Guideline on the Use of Thiopurines , Methotrexate , and Anti – TNF-a Biologic Drugs for the Induction and Maintenance of Remission in In fl ammatory Crohn ’ s Disease , 2022 .